116 related articles for article (PubMed ID: 12372512)
1. Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 1: identification and structure-activity relationships.
Zhao H; Thurkauf A; He X; Hodgetts K; Zhang X; Rachwal S; Kover RX; Hutchison A; Peterson J; Kieltyka A; Brodbeck R; Primus R; Wasley JW
Bioorg Med Chem Lett; 2002 Nov; 12(21):3105-9. PubMed ID: 12372512
[TBL] [Abstract][Full Text] [Related]
2. Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation.
Zhao H; He X; Thurkauf A; Hoffman D; Kieltyka A; Brodbeck R; Primus R; Wasley JW
Bioorg Med Chem Lett; 2002 Nov; 12(21):3111-5. PubMed ID: 12372513
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P; Coolen HK; Keizer HG; van Hes R; de Moes JP; den Hartog AP; Stork B; Plekkenpol RH; Niemann LC; Stroomer CN; Tulp MT; van Stuivenberg HH; McCreary AC; Hesselink MB; Herremans AH; Kruse CG
J Med Chem; 2005 Nov; 48(22):6855-69. PubMed ID: 16250644
[TBL] [Abstract][Full Text] [Related]
4. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
[TBL] [Abstract][Full Text] [Related]
5. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR
J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
Terzioglu N; van Rijn RM; Bakker RA; De Esch IJ; Leurs R
Bioorg Med Chem Lett; 2004 Nov; 14(21):5251-6. PubMed ID: 15454206
[TBL] [Abstract][Full Text] [Related]
7. N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.
Newman AH; Cao J; Bennett CJ; Robarge MJ; Freeman RA; Luedtke RR
Bioorg Med Chem Lett; 2003 Jul; 13(13):2179-83. PubMed ID: 12798330
[TBL] [Abstract][Full Text] [Related]
8. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
[No Abstract] [Full Text] [Related]
9. trans-1-[(2-Phenylcyclopropyl)methyl]-4-arylpiperazines: mixed dopamine D(2)/D(4) receptor antagonists as potential antipsychotic agents.
Zhang X; Hodgetts K; Rachwal S; Zhao H; Wasley JW; Craven K; Brodbeck R; Kieltyka A; Hoffman D; Bacolod MD; Girard B; Tran J; Thurkauf A
J Med Chem; 2000 Oct; 43(21):3923-32. PubMed ID: 11052797
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.
Vangveravong S; Zhang Z; Taylor M; Bearden M; Xu J; Cui J; Wang W; Luedtke RR; Mach RH
Bioorg Med Chem; 2011 Jun; 19(11):3502-11. PubMed ID: 21536445
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
[TBL] [Abstract][Full Text] [Related]
13. 6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors.
Hodgetts KJ; Kieltyka A; Brodbeck R; Tran JN; Wasley JW; Thurkauf A
Bioorg Med Chem; 2001 Dec; 9(12):3207-13. PubMed ID: 11711296
[TBL] [Abstract][Full Text] [Related]
14. Identification of a new selective dopamine D4 receptor ligand.
Sampson D; Zhu XY; Eyunni SV; Etukala JR; Ofori E; Bricker B; Lamango NS; Setola V; Roth BL; Ablordeppey SY
Bioorg Med Chem; 2014 Jun; 22(12):3105-14. PubMed ID: 24800940
[TBL] [Abstract][Full Text] [Related]
15. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G
J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and discovery of 5-piperazinyl-1,2,6,7-tetrahydro-5H-azepino[3,2,1-hi]indol-4-one derivatives: a novel series of mixed dopamine D2/D4 receptor antagonist.
Zhao H; Zhang X; Hodgetts K; Thurkauf A; Hammer J; Chandrasekhar J; Kieltyka A; Brodbeck R; Rachwal S; Primus R; Manly C
Bioorg Med Chem Lett; 2003 Feb; 13(4):701-4. PubMed ID: 12639562
[TBL] [Abstract][Full Text] [Related]
18. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
[TBL] [Abstract][Full Text] [Related]
19. Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213).
Löber S; Hübner H; Utz W; Gmeiner P
J Med Chem; 2001 Aug; 44(17):2691-4. PubMed ID: 11495580
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.
Kesten SR; Heffner TG; Johnson SJ; Pugsley TA; Wright JL; Wise LD
J Med Chem; 1999 Sep; 42(18):3718-25. PubMed ID: 10479303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
